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Background Occluding plaques are commonly found in 
the infrarenal aorta and the iliac artery in patients with pe-
ripheral arterial disease (PAD). Aortoiliacocclusive disease 
(AIOD) occurs commonly in patients with PAD. 
Methods: This is a prospective study was carried out be-
tween 2015 and 2017 in Sina hospital. Patients with oc-
clusion in aortoiliac artery and its branches were included. 
Stent was placed for patients, if they had any obstruction 
or stenosis in aortoiliac artery in angiography. Patients 
were examined in terms of clinical status and ABI calcu-
lation and underwent Color Doppler ultrasound of aor-
toiliac artery to determine patency rate at 1, 3, 12, and 24 
months after stent placement. 
Results: The mean age of patients was 64.60 (±10.41). 
The main symptoms of the patients were claudication 
(41.8%), ulcer (27.3%), pain at rest (20%), and gangrene 
(20%). The lesion was bilateral in 21 patients (38.2%). 
According to TASC stratification, lesions were of type A in 
26 patients (47.3%), type B in 4 patients (7.3%), type C 
in 5 patients (9.1%), and type D in 20 patients (36.4%). 
The six-month, one-year, and two-year patency rates were 
89.1%, 83.6%, and 72.7%, respectively. The mean an-
nual ABI of patients was 0.79 (±0.11) and two year ABI 
was 0.68 (±0.1). 
Conclusion: It seems that stenting and angioplasty are 
effective in improving patients’ conditions and result in a 
good short and medium-term patency. 
Keywords: Aortoiliac artery occlusion, patency rate, en-
dovascular stenting, intraarterial stenting. 
Occluding plaques causing atherosclerotic obstructive dis-
ease are commonly found in the infrarenal aorta as well 
as iliac artery in patients with peripheral arterial disease 
(PAD)1. Atherosclerotic plaques can cause symptoms in 
distal vessels, due to blockage of blood flow, detachment 
and embolization of atherosclerotic or thrombotic debris. 
If the plaques become large enough to affect the arterial 
lumen, blood flow to the distal organs will be decreased1,2. 
Aortoiliac occlusive disease (AIOD) occurs commonly in 
patients with PAD. Significant lesions in the aortoiliac 
arterial wall can be easily detected by checking femoral 
pulses. Any reduction in the femoral palpable pulse sug-
gests that the blockage is proximal to the femoral pulses. 
Occlusive lesions can be present in the infrarenal aorta, 
common iliac, internal iliac (hypogastric), external iliac or 
any or all of these arteries3,4.
Surgical treatment of AIOD has been remained corn stone 
has remained the corner stone of treatment for many 
years and had somewhat favorable outcomes. Techniques 
such as percutaneous transluminal angioplasty (PTA) and 
stenting can be considered as alternative to open surgery 
for patients who are not proper candidates for surgical 
repair. Catheter-based endovascular therapies for AIOD 
have fewer benefits (?) in terms of morbidity, faster recov-
ery, and shorter hospitalization. In fact, most endovascular 
interventions are easily performed in outpatient settings3,4.
Regarding the mentioned issues, the present study aims 
to determine the survival rate and possible contributing 
factors in the clinical outcomes of patients with aortoiliac 
artery occlusion undergoing intra-arterial stenting.
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his prospective study was carried out on pa-
tients presented at outpatient vascular surgery 
clinic of Sina hospital from 2015 to 2017 with 
occlusion of aortoiliac artery and its branches, and subse-
quently, they were selected for angiography. Co2 CO2 an-
giography was considered for those who had raised cre-
atinine level. Stent was placed for patients, if they had any 
obstruction or stenosis in aortoiliac artery in angiography. 
In this study, the exposure refers to patients with stenosis 
and obstruction of the common iliac or external iliac ar-
teries, or both, diagnosed after angiography and the out-
come refers to patients who underwent stenting during 
angiography after diagnosis. Variables include smoking, 
disease manifestations, comorbidities, symptoms onset to 
treatment onset interval, signs of limb ischemia, degree of 
artery stenosis and obstruction, anatomical site of stenosis, 
TASC II stratification, patency rate, 1-year prognosis, and 
ABI were gathered. Patients with poor compliance, rheu-
matologic diseases, due to the possible misdiagnosis of 
pain, were excluded from the study. The inclusion criteria 
were the eligible patients aged from 50 to 80 years with 
manifestations of arterial obstruction. The patients were 
examined clinically, ABI was calculated for each one, and 
patients underwent Color Doppler Ultrasound of aortoiliac 
artery for patency rate at 1, 3, 12, and 24 months after 
stent placement. Patency rates at four intervals and one- 
and tow-year two-year ABI were considered as the final 
outcomes of the study and the relationship of these vari-
ables with other parameters of the study was determined.
Statistical analysis was accomplished using the Statistical 
Package for Social Sciences (SPSS 16, SPSS Inc., Chicago, 
US). Data are expressed as number (%) or mean ± stan-
dard deviation (SD).
he mean age of patients, including 48 males 
(87.3%) and 7 females (12.7%), was 64.6 
(±10.41) years. Forty-three patients (78.2%) 
had a history of smoking. The underlying diseases were hy-
pertension, diabetes mellitus, hyperlipidemia, heart failure, 
and renal failure in 19 (34.5%), 26 (47.3%), 7 (12.7%), 8 
(14.5%), and 19 (1.8%) patients, respectively. The drugs 
used by patients were aspirin, warfarin, beta-blockers, 
Plavix, statins and insulin in 29 (52.7%), 2 (3.6%), 5 
(9.1%), 8 (14.5%), 18 (32.7%), and 2 (3.6%), respectively. 
The main symptoms of the patients were claudication, ul-
cer, rest pain, and gangrene in 23 (41.8%), 15 (27.3%), 
11 (20%), and 11 (20%), respectively. The lesion (lesion 
has not been mentioned up to here) was at the right side, 
at the left side, bilaterally in 21 (38.2%), 12 (21.8%), 21 
(38.2%), respectively. The interval between symptoms on-
set and treatment was less than 3 months in 6 patients 
(10.9%) whereas more than 3 months in 43 patients 
(78.2%). In patients whose symptoms had started more 
than 3 months, the mean interval between symptoms on-
set and treatment was 8.15 (±2.54) months. According to 
TASC stratification, lesions were type A, type B, type C, 
type D in 26 (47.3%), 4 (7.3%), 5 (9.1%), and 20 (36.4%) 
patients, respectively. The mean diameter of the vessel 
was 7.82 (±1.16) mm and the mean length of the lesion 
was 6.34 (±6.42) cm. The mean minimum stenosis was 
81.18 (±8.86) percent prior the treatment.
The type of stent used was self-expanding in 37 patients 
(67.3%) and balloon-expanding in 18 patients (32.7%). 
The largest diameter of the stent was averagely 70.86 
(±45.25) mm. The mean number of stents used was 1.83 
(±0.97). The initial success was achieved in 98.70% of the 
cases (number of patients should be mentioned). Ultra-
sound performed after a month, 6 months, 1 year, 2 years, 
revealed that 0 (0.0%), 5 (9.1%), 8 patients (14.5%), 2 
years, 11 patients (20%) had developed stenosis or ob-
struction, respectively. The mean 1 and 2-year calculated 
ABI of the patients was 0.79 (±0.11) and 0.68 (±0.1).
There was a significant difference between HLP and 
one-year ABI (p-value: 0.011). There was significant dif-
ference between claudication and one-year patency (p-
value: 0.008). There was significant difference between 
two-year patency (p-value: 0.044). There was significant 
difference between and one-year ABI (p-value< .001). 
There was significant difference between gangrene and 
six-month patency (p-value: 0.021) and one-year ABI (p-
value: 0.005). There was significant difference between 
TASC stratification and six-month patency (p-value: 
0.010). There was significant difference between number 
of lesions with six-month patency (p-value: 0.011). There 
was significant difference between the maximum lesion 
diameter and six-month patency (p-value: 0.042). There 
was significant difference between and the number of 
stents and six-month patency (p-value: 0.042). The loca-
tion of the disease was significantly differed among differ-
ent TASC groups (p=0.015), so that 61.9% were bilateral 
TASC D and 57.1% unilateral TASC A. The relationship of 
between one and 2-year ABI and patency rate was statisti-
cally significant (p-value<001). (Table 1). 
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Table 1. Showing correlation between all studied variables 
and 6 month 1 year and 2 year patency rate as well as 1 
year ABI. 
Parameter 6-month patency
1-year 
patency
2-year 
patency
1-year 
ABI
Age 0.635 0.493 0.945 0.469
Gender 0.374 0.245 0.636 0.078
Smoking 0.902 0.731 0.480 0.051
HTN 0.516 0.885 0.935 0.156
DM 0.708 0.329 0.487 0.752
HLP 0.631 0.967 0.636 0.011*
HF 0.738 0.845 0.622 0.866
Renal Failure 0.753 0.681 0.056 0.702
ASA 0.708 0.597 0.794 0.752
Warfarin 0.653 0.557 0.459 0.479
Betablocker 0.394 0.337 0.301 0.115
Plavix 0.374 0.845 0.141 0.130
Statin 0.649 0.595 0.439 0.862
Insulin 0.653 0.159 0.328 0.479
Claudication 0.053 0.008* 0.044* 0.000*
Ulcer 0.924 0.004* 0.860 0.932
Rest Pain 0.243 0.126 0.764 0.725
Gangrene 0.021* 0.139 0.241 0.005*
Unilateral/
Bilateral 0.029* 0.624 0.639 0.423
Symptom to 
therapy interval 0.559 0.729 0.786 0.774
TASC 0.010* 0.580 0.254 0.511
Reference vessel 
diameter 0.446 0.843 0.246 0.056
Lesion length 0.311 0.947 0.886 0.381
Occlusion 
severity 0.431 0.385 0.472 0.582
Number of 
lesions 0.011* 0.388 0.283 0.878
Stent Type 0.516 0.218 0.237 0.643
Highest diameter 
of stent 0.042* 0.315 0.681 0.747
Number of stents 0.042* 0.705 0.254 0.830
*shows statistically significant values.
s expected, the disease is most preva-
lent at a particular age. Accordingly, 
in the study of Van Haren RM et al5 
in 2017, the mean age of patients was 59 years. In the 
study of Rzucidlo Em et al.6, the mean age of patients was 
63 years. Indes JE et al.7 stated that patients undergoing 
stenting are more likely to be over 65 years (54%), and to 
be female. The latter study is the only study in which the 
number of females was more than males.
There was a history of smoking in 43 (78.2%) of patients. 
The most common underlying diseases were diabetes mel-
litus (47.3%) and hypertension (34.5%). In the study of 
Rzucidlo Em et al.6, 71% of patients were active smokers 
and hypertension was observed in 91%, diabetes in 26%, 
and renal failure in 21% of patients. The rate of renal fail-
ure in the present study was 1.8%. In current study, there 
was a relationship between hyperlipidemia and one-year 
ABI (p=0.011), so that, the higher levels of lipid profile, 
the lower one year ABI. Despite hyperlipidemia, the prob-
ability of ABI of less than 0.9 increased after one year. In 
a study by Kashyap VS et al.8 (2008), hyperlipidemia and 
smoking led to poor outcomes in stenting and angioplasty 
compared to ABI. In the study of Kashyap VS et al.4, dia-
betes mellitus had an inverse relation with patency rate8.
The main symptoms in the present study were claudica-
tion, ulcer, resting pain, and gangrene, in descending or-
der. In the study of Kashyap VS et al.8, claudication was 
observed in 53%, resting pain in 28%, and gangrene 
and limb ischemia in 19% of patients; the findings of this 
study are similar to that of ours. In the study of Van Haren 
RM et al.5, 100% of patients had resting pain and 40% 
had gangrene, which is completely in contrast with our 
findings. In a study by Rzucidlo Em et al.6, resting pain 
was observed in 65% of patients and gangrene and limb 
amputation in 35% of patients.
The relationship of the number of symptoms with oth-
er parameters was statistically significant in the present 
study. Claudication was statistically significant with one-
year and two-year patency and one-year ABI, worsening 
the prognosis of the patient. Ulcers, also, significantly re-
duced the one-year patency, while gangrene significantly 
reduced the six-month patency as well as one-year ABI. 
In this study, 38.2% of cases were bilateral and 60% 
were unilateral and there was a significant relationship 
between bilateral disease and less significant six-month 
patency rate, which is similar to the results of a study by 
Lun Y et al.9. 
The most common lesions in our study were TASC A, type 
D, type C, and type B, in descending order. In the study 
of RevueltaSuero et al.10, as with the present study, TASC 
A lesions were the more common lesion. In the study of 
Rzucidlo Em et al6, TASC C and D lesions were the com-
mon lesions in 85% of cases. The TASC type had a sig-
nificant relationship with six-month patency in our study, 
so the more severe TASC group, the less patency rate. In 
numerous studies, TASC types had statistically significant 
relationship with the procedure and its clinical outcomes. 
Accordingly, Benetis et al.11 found that endovascular pro-
cedure in TASC A lesions can lead to more complications 
compared to other interventions, and it is not a preferred 
method, while endovascular procedure can bring benefi-
cial clinical outcomes in the other three types of TASC.
The mean length of lesions was 6.34 cm in the present 
study. In the study of Rzucidlo Em et al.6, the mean length 
of lesions was 13.7 cm. The study by RevueltaSuero et 
al.10 reported a mean lesion length of 42 mm. There was 
no correlation in the present study between the lesion 
length and other parameters of the study, but Karpenko 
AA et al.12 concluded that increasing the lesion length to 
more than 100 mm was associated with restenosis or sub-
sequent thrombosis.
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The largest stent diameter in our study was averagely 70.86 
mm. This diameter has a significant relationship with the 
six-month patency and larger stent diameter has led to 
lower patency rate. In a study by Kavaliauskienė et al.13, 
stents smaller than 61 mm had 12-month and 24-month 
patency rates of 90.6% and 86.6%, respectively, while 
stents larger than 61 mm had 12- month and 24-month 
patency rates of 67.7% and 60.2%, respectively.
In the present study, the initial success rate was 98.70%. 
In the study of Kashyap VS [8], the success rate was 96%. 
Van Haren RM5 reported a success rate of 100%. This was 
95% in the study of Yuan L14. In general, the findings of 
most studies are to a great degree similar in terms of pri-
mary success rate.
Patency was the most important indicator in this study, 
which was 100% in the first month, 89.1% in 6 months, 
83.6% in 1 year, and 72.7% in 2 years. One-year and 
3-year patency rates were 86% and 80%, respectively 
in the study of Indes JE et al.4. In a study by Jongkind V 
et al.3, the 4-year/ 5-year patency rates were 80%-98%. 
The three-year patency in the study of Kashyap VS et al.8 
was 74%. One-year and 2-year patency rates were 92.7% 
and 81.9%, respectively in the study of Karpenko AA et 
al.12. The one-year patency reported by Van Haren RM et 
al.5 in 2017 was 80%. Lun Y9 reported one-year, 3-year, 
and 5-year patency rates as 91.4%, 81.8%, and 64.2%, 
respectively. The 6-month, 18-month, and 24-month pa-
tency rates were 93.3%, 83%, and 66.4%, respectively 
in the study of Yuan L et al.14. The one-year patency was 
91% in the study of Psacharopulo D et al.15. In our study, 
the number of stents was significantly associated with a 
decrease in six-month patency rate.
Changes in ABI have been recorded as one of the most 
important indicators after the procedure in various stud-
ies. In here, ABI was evaluated 1 and 2 years after the trial, 
which was 0.79 and 0.68. The study by Van Haren RM et 
al.5 has shown that ABI is improved in both left and right 
legs by 0.5. In the study of Rzucidlo Em et al6, ABI was 
increased from 0.3 to 0.59. In the study of Kashyap VS et 
al.8, ABI reached from 0.48 to 0.84.
Limitations
Failure to measure ABI prior to the procedure was one of 
the drawbacks of the present study, which should be con-
sidered in future studies in order to allow its comparison 
before and after intervention and to calculate recovery af-
ter the procedure.
ccording to the findings of this study, 
it seems that stenting and angioplas-
ty (irrespective of the stent type, i.e. 
self-expanding or balloon-expanding) are effective in im-
proving patients, resulting in a good short- and medium-
term patency. In addition, due to the strong association 
between patency rate and symptoms (i.e. claudication, 
gangrene, and ulcer) patients should be further evaluated 
in terms of these symptoms.
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